Holen Sie sich die Stockscreener-App
25.52
1.27%
0.32
Handel nachbörslich:
25.52
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance Australia
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Gene therapy shows promise in Canavan disease trial By Investing.com - Investing.com Australia
Citi reiterates Buy rating on BridgeBio shares, cites clinical results By Investing.com - Investing.com Canada
Gene therapy shows promise in Canavan disease trial - Investing.com
BridgeBio Shares Positive Data from High Dose Cohort of - GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene - The Bakersfield Californian
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - StockTitan
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Objective long/short (BBIO) Report - Stock Traders Daily
Scotiabank Initiates Coverage of BridgeBio Pharma (BBIO) with Sector Outperform Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $46.00 by Analysts at Leerink Partners - MarketBeat
Equities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO) - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for BBIO Earnings - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at Scotiabank - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 4.7%Time to Buy? - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market Emerging - openPR
BridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6%Here's What Happened - MarketBeat
When the Price of (BBIO) Talks, People Listen - Stock Traders Daily
Marshall Wace LLP Invests $781,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
3 Top Stocks That Could Still Rocket Higher in 2024 - AOL
Algert Global LLC Has $1.42 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Oppenheimer Initiates Coverage of BridgeBio Pharma (BBIO) with Perform Recommendation - Nasdaq
BridgeBio granted Perform rating at Oppenheimer on market challenges (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Oppenheimer - MarketBeat
BridgeBio to Present Outcomes Data Through 42 Months from - GlobeNewswire
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - StockTitan
Ghisallo Capital Management LLC Sells 33,750 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Cut by Ghisallo Capital Management LLC - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Quarry LP - Defense World
5 FDA decisions to watch in the fourth quarter - Yahoo Finance
Capital Impact Advisors LLC Reduces Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio completes enrollment for potential LGMD2I therapy By Investing.com - Investing.com South Africa
BridgeBio shares maintain Market Perform rating from BMO By Investing.com - Investing.com Canada
Piper Sandler keeps Overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com Canada
BridgeBio shares hold ratings with positive study data By Investing.com - Investing.com Canada
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - AOL
Early-Stage Biotech BridgeBio's Acoramidis Drives Valuation for Long-Term Investors - Morningstar
Transthyretin Amyloid Cardiomyopathy Market Size, Share, - openPR
BridgeBio Pharma's (BBIO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
BridgeBio's SWOT analysis: genetic disease innovator's stock faces market challenges - Investing.com
BridgeBio Pharma (NASDAQ:BBIO) Stock Rating Reaffirmed by HC Wainwright - Defense World
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) - The Manila Times
BridgeBio Completes Enrollment of FORTIFY, Phase 3 - GlobeNewswire
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Reduced by Perceptive Advisors LLC - MarketBeat
Vanguard Personalized Indexing Management LLC Purchases 1,617 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio completes enrollment for potential LGMD2I therapy - Investing.com
Short Interest in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Increases By 10.7% - MarketBeat
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):